Home

  • Home
    • » e-Newsletters

IDSA issues guidelines for community-acquired pneumonia

Infection Control Monitor, January 2, 2004

The Infectious Diseases Society of America (IDSA) this month released new pneumonia and influenza guidelines to help physicians manage the treatment of patients with lung disease. The society updates the guidelines every few years to account for evolving resistance to antimicrobials and other advances. The latest version introduces new diagnostic and management strategies, including suggestions for initial empiric therapy for community-acquired pneumonia (CAP).

Since the cause of pneumonia is often difficult to determine, physicians usually begin treatment with antibiotics, which cover a broad range of pathogens. Previous versions of the guidelines included numerous drug options for the treatment of CAP, including fluoroquinolones, which are widely used to treat pneumonia.

The committee that updated the guidelines became concerned about misuse and overuse of fluoroquinolones, which could lead to the demise of fluoroquinolones as useful antibiotics within the next five to 10 years. Since the last revision in 2000, several compounds have been withdrawn because of serious safety concerns, and increasing resistance to this class of drugs. The guidelines include a table that lists the recommended treatment options for different situations. They also provide strategies on new topics such as CAP in the elderly and SARS.

Most Popular